- Home
- LRFC vs MAIA Comparison
LRFC vs MAIA Comparison
Compare LRFC & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRFC
- MAIA
- Stock Information
- Founded
- LRFC 2013
- MAIA 2018
- Country
- LRFC United States
- MAIA United States
- Employees
- LRFC N/A
- MAIA N/A
- Industry
- LRFC Finance: Consumer Services
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- LRFC Finance
- MAIA Health Care
- Exchange
- LRFC Nasdaq
- MAIA Nasdaq
- Market Cap
- LRFC 49.8M
- MAIA 46.7M
- IPO Year
- LRFC 2013
- MAIA 2022
- Fundamental
- Price
- LRFC $18.30
- MAIA $2.15
- Analyst Decision
- LRFC
- MAIA
- Analyst Count
- LRFC 0
- MAIA 0
- Target Price
- LRFC N/A
- MAIA N/A
- AVG Volume (30 Days)
- LRFC 9.4K
- MAIA 79.7K
- Earning Date
- LRFC 05-08-2025
- MAIA 05-13-2025
- Dividend Yield
- LRFC 7.68%
- MAIA N/A
- EPS Growth
- LRFC N/A
- MAIA N/A
- EPS
- LRFC N/A
- MAIA N/A
- Revenue
- LRFC $20,916,000.00
- MAIA N/A
- Revenue This Year
- LRFC N/A
- MAIA N/A
- Revenue Next Year
- LRFC N/A
- MAIA N/A
- P/E Ratio
- LRFC N/A
- MAIA N/A
- Revenue Growth
- LRFC 3.66
- MAIA N/A
- 52 Week Low
- LRFC $17.30
- MAIA $1.40
- 52 Week High
- LRFC $26.00
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- LRFC 34.59
- MAIA 70.43
- Support Level
- LRFC $17.94
- MAIA $1.51
- Resistance Level
- LRFC $18.78
- MAIA $1.61
- Average True Range (ATR)
- LRFC 0.89
- MAIA 0.12
- MACD
- LRFC 0.07
- MAIA 0.06
- Stochastic Oscillator
- LRFC 38.81
- MAIA 90.91
About LRFC Logan Ridge Finance Corporation
Logan Ridge Finance Corp an externally managed non-diversified closed-end management investment company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company offers customized financing to business owners, management teams, and financial sponsors for change of ownership transactions, recapitalizations, strategic acquisitions, business expansion, and other growth initiatives.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.